1 August 9, 2024 Second Quarter 2024 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not ...

Legend Biotech Overview - Legend Biotech's shares rose 12 1% on Friday following a takeover bid report from an unidentified bidder [10] - The company hired investment banking firm Centerview Partners to review the takeover offer [11] - Legend Biotech currently has only one marketed product, Carvykti, an autologous CAR-T cell therapy for multiple myeloma (MM), marketed in partnership with Johnson & Johnson [12] Carvykti and Abecma Comparison - Carvykti and Abecma are both FDA-approved CAR-T therapies with similar mechanisms, but Carvykti has an edge due to its use as an earlier line of treatment in MM patients [2] - The FDA granted label expansion to Carvykti in April, allowing it to treat adult MM patients who have received at least one prior line of therapy, compared to its previous fifth-line treatment approval [7] - Before the label expansion, only 15% of initially diagnosed MM patients in the US could start a fifth line of therapy, but the new label is expected to cater to a wider patient population [8] Manufacturing and Revenue Potential - Johnson & Johnson claims to have more than doubled its manufacturing capacity last year in anticipation of increased demand for Carvykti post-label expansion [8] - The new labels for both Carvykti and Abecma are expected to boost their revenue-generating potential [2] Industry and Competitor Impact - Legend Biotech's rival, 2seventy bio (TSVT), also saw a 7% increase in shares on July 12 due to the takeover report [1] - 2seventy bio markets Abecma in partnership with Bristol Myers, which also received FDA label expansion for treating adults with r/r MM who have received two or more prior lines of therapy [4] Stock Performance - Year to date, Legend Biotech's shares have lost 9 7% compared to the industry's 2 6% fall [5]

1 May 13, 2024 First Quarter 2024 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not bee ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 6-K ________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: May 13, 2024 Commission File Number: 001-39307 ________________________________ Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) ________________________________ 2101 Cottontail Lane Somerset, New Jersey 08873 ...

Investors are always looking for stocks that are poised to beat at earnings season and Legend Biotech Corporation (LEGN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Legend Biotech is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights SOMERSET, N.J.—March 11, 2024— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights. "With worldwide sales of half a billion dollars in its first full year of commercialization, our rapid, successful launch of CARVYKTI reinforces its position as a leading CAR-T therapy for p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 6-K ________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 20, 2023 Commission File Number: 001-39307 ________________________________ Legend Biotech Corporation (Exact Name of Registrant as Specified in its Charter) ________________________________ 2101 Cottontail Lane Somerset, New Jersey 0 ...

Exhibit 99.1 Legend Biotech Reports First Quarter 2023 Results and Recent Highlights SOMERSET, N.J.--(BUSINESS WIRE)--May 18, 2023--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results. "We are extremely pleased to announce that we have recently raised $762 million in funding. With this substantial capital in ...

SOMERSET, N.J.--(BUSINESS WIRE)--March 30, 2023--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its full year 2022 audited financial results. Exhibit 99.1 Legend Biotech Reports Full-Year 2022 Results and Recent Highlights "2022 was a year of significant milestones for Legend Biotech, marked by the regulatory approvals of CARVYKTI® in the U.S., Europe, ...